Article
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
The New England journal of medicine - 29 Oct 2020
Wu Yi-Long, Tsuboi Masahiro, He Jie, John Thomas, Grohe Christian, Majem Margarita, Goldman Jonathan W, Laktionov Konstantin, Kim Sang-We, Kato Terufumi, Vu Huu-Vinh, Lu Shun, Lee Kye-Young, Akewanlop Charuwan, Yu Chong-Jen, de Marinis Filippo, Bonanno Laura, Domine Manuel, Shepherd Frances A, Zeng Lingmin, Hodge Rachel, Atasoy Ajlan, Rukazenkov Yuri, Herbst Roy S
Abstract excerpt
BACKGROUND: Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown. METHODS: In this double-blind, phase 3 trial, we randomly assigned patients with completely resected EGFR mutation-positive NSCLC in a 1:1 ratio to receive either...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.